ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer's Disease Program
(Thomson Reuters ONE) -
Company Focused on Development of Antibodies that Selectively Target Toxic,
Prion-Like Forms of Amyloid beta
ProMIS Issues White Paper from AAIC Presentations Outlining Role of Toxic
Misfolded Forms of Amyloid beta and Tau in Alzheimer's Disease
TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 19, 2017 - ProMIS
Neurosciences, Inc., a biotechnology company focused on the discovery and
development of precision treatments for neurodegenerative diseases, today
announced the presentation of its precision design approach and preclinical data
for its lead product candidates, at the Alzheimer's Association International
Conference (AAIC) being held in London from July 16-20.
Below are key highlights of the presentation by Kaplan et al., entitled
Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310:
Precision drug design for Alzheimer's disease:
* Use of ProMIS proprietary computational modeling allowed the identification
and generation of monoclonal antibodies (mAbs) against specific targets
(epitopes) on toxic forms of amyloid beta oligomers (AbetaO), a recognized
root cause of Alzheimer's disease.
* Lead product candidates PMN310 and PMN350 were selected on the basis of
their ability to selectively target and neutralize toxic AbetaO with no
significant cross-reactivity (binding) to amyloid beta monomers or fibrils.
Antibody protection against the neurotoxicity of AbetaOs was demonstrated in
cultures of neurons and in a mouse model where antibody administration
prevented AbetaO-induced loss of short term memory formation and inhibited
inflammation and synaptic damage.
* Detection by ProMIS mAbs of target epitopes in cerebrospinal fluid (CSF)
from Alzheimer's patients offers potential for precision medicine as reports
of different prion-like strains of AbetaO may preclude an effective "one
size fits all" approach to treating Alzheimer's. Confirming the presence of
the specific target prior to treatment would allow for treatment of the
right patient with the right antibody.
Commenting on the ProMIS podium presentation at AAIC, Eugene Williams, ProMIS
Executive Chairman stated: "We continue to make significant progress with our
Alzheimer's program, selectively targeting toxic amyloid beta oligomers, widely
recognized at the conference to be a root cause of Alzheimer's. The unique
characteristics of our lead products in development, PMN310 and PMN350,
distinguishes them from other antibodies targeting amyloid beta currently
undergoing clinical trials and are designed to address observed issues of safety
and efficacy".
Several presentations at the AAIC meeting by other specialist groups in the
field also underlined the importance of selectively targeting and neutralizing
toxic AbetaO for effective treatment of Alzheimer's.
A white paper, summarizing these reports, as well as offering more detailed
information on the ProMIS AAIC presentation is available on the ProMIS
Neurosciences website at: http://bit.ly/2u4yp5t
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO),
headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts.
The mission of ProMIS is to discover and develop precision medicine therapeutics
for effective treatment of neurodegenerative diseases, in particular Alzheimer's
disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
cbealamaro(at)streetwisereports.com
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 19.07.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 553008
Anzahl Zeichen: 7257
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer's Disease Program"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
